Vigen Dr. Nattokinase
Natto Bacillus, Banaba Leaf
Vigen Medical
Human Otc Drug
NDC 82437-030Vigen Dr. Nattokinase also known as Natto Bacillus, Banaba Leaf is a human otc drug labeled by 'Vigen Medical'. National Drug Code (NDC) number for Vigen Dr. Nattokinase is 82437-030. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Vigen Dr. Nattokinase drug includes Lagerstroemia Speciosa Leaf - 45 mg/500mg Nattokinase - 67 mg/500mg . The currest status of Vigen Dr. Nattokinase drug is Active.
Drug Information:
| Drug NDC: | 82437-030 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Vigen Dr. Nattokinase |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Natto Bacillus, Banaba Leaf |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Vigen Medical |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | LAGERSTROEMIA SPECIOSA LEAF - 45 mg/500mg
NATTOKINASE - 67 mg/500mg
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED DRUG OTHER |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Dec, 2021 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 11 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Vigen medical
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 8809292030236
|
| UPC stands for Universal Product Code. |
| UNII: | OUK5B3W9E4
H81695M5OP
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 82437-030-02 | 30 BLISTER PACK in 1 CARTON (82437-030-02) / 500 mg in 1 BLISTER PACK (82437-030-01) | 01 Dec, 2021 | N/A | No |
| 82437-030-03 | 60 BLISTER PACK in 1 CARTON (82437-030-03) / 500 mg in 1 BLISTER PACK (82437-030-01) | 01 Dec, 2021 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose improve blood circulation suppress blood sugar
Product Elements:
Vigen dr. nattokinase natto bacillus, banaba leaf nattokinase nattokinase lagerstroemia speciosa leaf lagerstroemia speciosa leaf yellow wax soybean oil
Indications and Usage:
Uses â natto bacillus culture powder it can help to improve blood circulation. â banaba leaf extract it can help to suppress blood sugar levels after meals.
Warnings:
Warnings â be sure to drink it with water as it may get stuck in your throat or uncomfortable. â if you have symptoms of gastrointestinal disorders or indigestion when ingesting, stop ingesting. â if you experience abnormal symptoms depending on your individual's physical condition, stop ingesting. â do not consume if there is anything wrong with product before ingestion. children, pregnant women and lactating women should be careful about their intake. â be careful of your intake before and after surgery. be careful when taking medicine (blood anticoagulants). â please be careful because you should not take the "dehumidifier" packaged separately for food quality control.
Dosage and Administration:
Directions â take 1 capsule once a day with sufficient water.
Package Label Principal Display Panel:
Package label 82437-030-02 : 30 tablets image of carton
Package label 82437-030-03 : 60 tablets image of carton
Further Questions:
Questions â customer call +82-1644-7582